| Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor G Wang, JW Barrett, M Stanford, SJ Werden, JB Johnston, X Gao, M Sun, ... Proceedings of the National Academy of Sciences 103 (12), 4640-4645, 2006 | 238 | 2006 |
| Targeting tumor vasculature with an oncolytic virus CJ Breitbach, NS De Silva, TJ Falls, U Aladl, L Evgin, J Paterson, YY Sun, ... Molecular Therapy 19 (5), 886-894, 2011 | 233 | 2011 |
| Immunopathogenesis of poxvirus infections: forecasting the impending storm MM Stanford, G McFadden, G Karupiah, G Chaudhri Immunology and cell biology 85 (2), 93-102, 2007 | 171 | 2007 |
| Synergistic interaction between oncolytic viruses augments tumor killing F Le Boeuf, JS Diallo, JA McCart, S Thorne, T Falls, M Stanford, F Kanji, ... Molecular Therapy 18 (5), 888-895, 2010 | 161 | 2010 |
| Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin XQ Lun, H Zhou, T Alain, B Sun, L Wang, JW Barrett, MM Stanford, ... Cancer research 67 (18), 8818-8827, 2007 | 128 | 2007 |
| Myxoma virus in the European rabbit: interactions between the virus and its susceptible host M Stanford, S Werden, G McFadden Veterinary research 38 (2), 299-318, 2007 | 120 | 2007 |
| Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients NL Berinstein, M Karkada, AM Oza, K Odunsi, JA Villella, JJ Nemunaitis, ... Oncoimmunology 4 (8), e1026529, 2015 | 105 | 2015 |
| Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo MM Stanford, M Shaban, JW Barrett, SJ Werden, PA Gilbert, ... Molecular Therapy 16 (1), 52-59, 2008 | 105 | 2008 |
| Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells MM Stanford, JW Barrett, SH Nazarian, S Werden, G McFadden Journal of virology 81 (3), 1251-1260, 2007 | 99 | 2007 |
| The relative activity of CXCR3 and CCR5 ligands in T lymphocyte migration: concordant and disparate activities in vitro and in vivo MM Stanford, TB Issekutz Journal of Leucocyte Biology 74 (5), 791-799, 2003 | 99 | 2003 |
| Myxoma virus and oncolytic virotherapy: a new biologic weapon in the war against cancer MM Stanford, G McFadden Expert opinion on biological therapy 7 (9), 1415-1425, 2007 | 97 | 2007 |
| First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer … NL Berinstein, M Karkada, MA Morse, JJ Nemunaitis, G Chatta, ... Journal of translational medicine 10, 1-12, 2012 | 96 | 2012 |
| Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors H MacTavish, JS Diallo, B Huang, M Stanford, F Le Boeuf, N De Silva, ... PLoS One 5 (12), e14462, 2010 | 85 | 2010 |
| ORFV: a novel oncolytic and immune stimulating parapoxvirus therapeutic JL Rintoul, CG Lemay, LH Tai, MM Stanford, TJ Falls, CT De Souza, ... Molecular therapy 20 (6), 1148-1157, 2012 | 81 | 2012 |
| Intravenously administered alphavirus vector VA7 eradicates orthotopic human glioma xenografts in nude mice JE Heikkilä, MJV Vähä-Koskela, JJ Ruotsalainen, MW Martikainen, ... PLoS One 5 (1), e8603, 2010 | 68 | 2010 |
| Myxoma virus is oncolytic for human pancreatic adenocarcinoma cells Y Woo, KJ Kelly, MM Stanford, C Galanis, Y Shin Chun, Y Fong, ... Annals of surgical oncology 15, 2329-2335, 2008 | 67 | 2008 |
| Innate immunity, tumor microenvironment and oncolytic virus therapy: friends or foes? MM Stanford, CJ Breitbach, JC Bell, G McFadden Current opinion in molecular therapeutics 10 (1), 32-37, 2008 | 58 | 2008 |
| Delineation of five thyroglobulin T cell epitopes with pathogenic potential in experimental autoimmune thyroiditis P Verginis, MM Stanford, G Carayanniotis The Journal of Immunology 169 (9), 5332-5337, 2002 | 57 | 2002 |
| A respiratory syncytial virus vaccine based on the small hydrophobic protein ectodomain presented with a novel lipid-based formulation is highly immunogenic and safe in adults … JM Langley, LD MacDonald, GM Weir, D MacKinnon-Cameron, L Ye, ... The Journal of infectious diseases 218 (3), 378-387, 2018 | 52 | 2018 |
| M-T5, the ankyrin repeat, host range protein of myxoma virus, activates Akt and can be functionally replaced by cellular PIKE-A SJ Werden, JW Barrett, G Wang, MM Stanford, G McFadden Journal of virology 81 (5), 2340-2348, 2007 | 51 | 2007 |
john w. barrettVerspeeten Family Cancer CentreVerified email at lhsc.on.ca
